Evaluation of the Safety of Deutetrabenazine at Higher Doses to Treat Chorea in Huntington’s Disease
Objective: To evaluate the safety and tolerability of deutetrabenazine >48 mg/d compared to ≤48 mg/d to treat Huntington’s disease (HD)–associated chorea in ARC-HD. Background: In…Evaluation of Cortical Excitability in Huntington’s Disease and Parkinson’s Disease
Objective: To evaluate the cortical excitability difference in Huntington's disease (HD) and Parkinson's disease (PD) using paired-pulse transcranial magnetic stimulation (TMS). Background: TMS is useful…Diagnostic accuracy of MR planimetry in clinically unclassifiable parkinsonism
Objective: To determine diagnostic accuracy of P/M, MRPI, and new indices termed P/M2.0 and MRPI2.0 (multiplying P/M and MRPI by third ventricle width/frontal horns width…Copper induced neurobehavioral features of Parkinson’s disease and oxidative stress and their abatement by Eugenol
Objective: The aim of this study was to evaluate impact of copper intoxication (10 mg/kg B.W) for 3 days on locomotor performance and oxidative status,…Management of Cervical Dystonia & Spastic Paresis with Botulinum Neurotoxin-A: results from the INPUT survey
Objective: To describe current practices among physicians using botulinum toxin-A (BoNT-A) to treat spastic paresis (SP) and cervical dystonia (CD). Background: BoNT-A is an effective…A novel phasic and restricted basal ganglia thalamocortical subcircuitry model
Objective: To advance a novel basal ganglia thalamocortical (BGTC) model that accounts for GPi as a tonic-burst mode regulator of the thalamus and for restricted…Stiff-person spectrum disorders in Russia: a retrospective analysis of 20 cases
Objective: We aimed to analyze clinical and immunologic features of a cohort of stiff-person spectrum disorder (SPSD) patients, who have been clinically managed by us…Bilateral vocal cord paralysis associated with idiopathic Parkinson’s disease
Objective: We present two cases of bilateral vocal cord paralysis (BVCP) associated with idiopathic Parkinson’s disease (iPD). Background: BVCP is a rare complication associated with…Development and Characterization of an Ultrasensitive Assay Platform for Detection of PD Associated alpha-Synuclein Oligomers in Human Blood
Objective: To develop a sensitive, specific and consistent detection of a-SynO in biofluids to provide a reliable biomarker for disease diagnosis, progression, and a theranostic…Can clinical outputs predict BDNF levels in people with Parkinson’s disease?
Objective: To modelling the relationship between Brain-Derived Neurotrophic Factor (BDNF) levels and clinical variables (stages of disease and cognition) in people with Parkinson's disease (PD).…
- « Previous Page
- 1
- …
- 19
- 20
- 21
- 22
- 23
- …
- 149
- Next Page »